Top Gastroenterologist Exposes What the PPI Industry Will Not Tell You - And Why Your Esophagitis Is Not Healing

I am going to say something that is going to make the pharmaceutical companies who manufacture omeprazole, pantoprazole, and esomeprazole very uncomfortable.

Because what I am about to explain could cost them $60 million in renewals they have quietly depended on this year alone.

Because what I am about to share explains why millions of people on long-term PPIs are still burning. Still avoiding food they love. Still sleeping on elevated pillows. Still being told at follow-up appointments that their esophagitis is "stable."

Stable is not better. Stable is managed. And managed means the drug is doing what it was designed to do — which is one of the three things your esophagus actually needs to heal.

After watching my own father take omeprazole for four years, reduce his acid, eat carefully, elevate his bed, do everything right — and still sit across from his gastroenterologist hearing the word stable while the lining of his esophagus had never once been given the signal to repair itself...

After finding the research that has been sitting in gastroenterology journals since 1971 that explains exactly why this happens and exactly what addresses it...

I am done staying quiet about what the PPI industry has chosen not to tell you.

It was a Tuesday afternoon in October.

My father had just come from his fourth annual follow-up endoscopy. Grade B erosive esophagitis, same as last year. Same as the year before that. Four years on pantoprazole. Four years of no coffee, no wine, dinner at six, head of the bed elevated on risers he bought online and assembled himself because the internet told him it would help.

He sat in my kitchen and put the report on the table and said: "She said stable again. Four years of doing everything right and it is still stable. What does stable actually mean, Sarah?"

I looked at the report. Grade B. Same grading as year one.

And I had to tell my father the truth that his gastroenterologist had not told him.

Stable means the acid is being suppressed. It does not mean the lining is healing. It means the erosion is not actively getting worse. It does not mean the tissue that was already eroded has repaired itself. Not one millimetre of it.

In four years of taking a pill every morning, doing everything he was told, my father's esophagus had been partially protected and completely unrepaired.

I went home that night and started writing.

Your PPI blocks the proton pumps in your stomach that produce acid. It reduces acid production by up to 95 percent.This is genuinely useful.

Acid was eroding your esophageal lining. Reducing the acid slows the erosion rate. The pill worked — for one of the three things your esophagus needs.

Repeated acid contact in your esophagus triggered a chronic inflammatory response — elevated IL-6, IL-8, TNF-alpha. The inflammatory proteins that keep damaged tissue in a constant breakdown state.

This inflammation does not switch off when acid production decreases. It has its own momentum.

Your gastroenterologist compares your latest scope to your previous one and says the erosion has not progressed.

What stable does not tell you is what the unrepaired, chronically inflamed tissue is doing between appointments.

The pharmaceutical model gives you a drug for what can be patented.

Acid suppression is patentable. Mucosal repair is not. Inflammation reduction via botanical extract is not.

So the protocol you have been on covers one of three mechanisms and calls it treatment.

This is not negligence. It is a business model.

And it is why your esophagitis is still "stable" after all this time.

When acid contacts your esophageal lining repeatedly it triggers an immune response — IL-6, IL-8, TNF-alpha flooding the area.

You started the PPI. The acid decreased. The inflammation did not.

Think of it this way.

You get a sunburn. You move out of the sun. The sunburned skin does not stop hurting the moment you walk indoors.

The PPI gets you indoors. The sunburn is still there. The tissue is still damaged. The inflammation is still running. And the inflammation is what is preventing the tissue from healing even though the acid is down.

This is why the burn does not fully resolve on a PPI. The acid is reduced. The inflamed tissue is still there — still reactive, still sending pain signals, still preventing repair.

Acid down does not mean inflammation down. Two separate mechanisms. Your PPI addresses one. The other has been running untreated the entire time you have been on medication.

"My father asked his gastroenterologist: is the tissue actually healing? She paused before she answered. That pause told me everything I needed to know."

Your esophageal mucosal cells have a specific biological repair pathway. Prostaglandin E2 synthesis. A signal that tells mucosal cells to produce protective mucus, renew damaged tissue, and rebuild the barrier that acid eroded.

No PPI activates this pathway. No antacid activates it. Nothing in the standard esophagitis protocol activates it.

A compound called deglycyrrhizinated licorice — DGL — was shown in clinical trials published in the journal Gut in 1971 and 1973 to stimulate prostaglandin E2 synthesis directly in gastric and esophageal mucosal cells.

In 1978 it matched Tagamet — the world's first blockbuster acid drug — in a head-to-head clinical trial for gastric ulcer healing.

This research has been sitting in published gastroenterology literature for over fifty years.

It is not in your treatment protocol because it cannot be patented. If Pfizer synthesised DGL tomorrow it would be in every gastroenterology guideline within five years. Because it is derived from licorice root it appears in no guideline at all. That is a commercial reason. Not a clinical one.

DGL does not reduce acid. It does not compete with your PPI. It rebuilds what the acid took away. That is the mechanism that has never been prescribed to you.

The repair mechanism exists. The evidence has existed since 1971. The compound that activates it exists. The only reason it was never prescribed to you is that it cannot be manufactured into a patent.

240% increase in protective mucus production with DGL in clinical studies

60% reduction in IL-6, IL-8, TNF-alpha with chamomile apigenin

1971 year DGL's mucosal repair mechanism was first peer-reviewed and published

The clinical trials that proved DGL works used between 380 and 760 milligrams per serving.

The most popular DGL product on pharmacy shelves today contains 75 milligrams. One tenth of the studied dose. The product was quietly reformulated years ago. The packaging looks identical. Nothing on the label indicates the dose changed.

And even at the right dose — the format matters enormously.

DGL needs to coat the esophageal lining to work. The esophagus is where the damage is.

A capsule dissolves in the stomach — the esophagus has already been bypassed entirely before any compound is released.

A gummy dissolves in the mouth. It coats the esophagus on the way down — delivering DGL directly to the damaged tissue it needs to repair. For esophageal damage, a capsule is the wrong delivery format. It sends the right ingredient to the wrong location.

You did not fail the ingredient. The ingredient was delivered at one tenth the dose to the wrong location. Those are solvable problems.

Wrong dose plus wrong format equals no result. 75mg in a capsule reaching the stomach is not what the 1971 trial studied. 400mg in a gummy coating the esophagus is.

PPI Acid reduction — your existing treatment covers this. Keep taking it. Your PPI reduces acid production significantly. That was the right first step. It was never designed to be the only step.

Chamomile 75mg for Tissue inflammation, never covered before. Now covered. Chamomile's apigenin inhibits NF-κB — the master inflammatory switch driving the IL-6, IL-8, and TNF-alpha keeping your esophageal tissue in chronic breakdown. German Commission E approved for GI inflammatory disease based on clinical evidence. When the inflammation drops the tissue environment finally allows healing to begin.60% reduction in key inflammatory markers in studies

DGL 400mg for Mucosal lining repair — never covered by standard protocol. Now covered. Stimulates prostaglandin E2 synthesis — the biological repair signal your esophageal mucosal cells need to produce protective mucus, renew tissue, and rebuild the barrier. At 400mg — five times the dose of the reformulated market-leading product. In a gummy that coats the esophagus from the first swallow — not a capsule that dissolves below it.

240% increase in protective mucus production in studies

Your esophagus is a tube. Fixed diameter. When chronic inflammation lays down scar tissue in a fixed-diameter tube, the tube gets narrower.

This is called stricture formation. It is documented. It is the direction unhealed esophageal inflammation travels.

The first sign is easy to dismiss. Food sitting slightly longer than it used to. A subtle resistance on certain textures.

Most people have noticed this already and attributed it to something else.

It is scar tissue. It has been building quietly since the inflammation started running without treatment.

Early stricture can be treated with dilation. Advanced stricture requires ongoing repeated intervention. The window to change direction is open now. It does not stay open indefinitely.

"Stable" is what the protocol produces when it covers one of three mechanisms and has nothing else to offer. It is not a verdict on your prognosis. It is a description of what one drug can do when used alone.

MILD. IMPROVED. Not just stable.

Stable is a pause on a trajectory. The trajectory of unhealed, chronically inflamed esophageal tissue runs toward stricture. Changing direction requires the two mechanisms your current protocol has never addressed.

Week 1–2 The Quiet Begins.

Chamomile starts suppressing the inflammatory response. The acute reactivity — the burn that arrives before you have done anything — starts to reduce. The tissue environment begins to change.

Week 2–3 The Morning Burn Fades.

The burn that greeted you before coffee starts arriving later, arriving softer, sometimes not arriving at all. DGL is building up and beginning to signal mucosal repair.

Week 4–6 The Food Comes Back.

Coffee without calculating the consequence. A glass of wine at dinner without waiting for what comes next. Foods you eliminated years ago becoming possible again — not because the acid changed, because the lining is no longer raw.

Month 2–3 MILD. IMPROVED.

At your next scope your gastroenterologist notes measurable improvement in the mucosal lining for the first time since diagnosis. She asks what you changed. You show her the 1971 paper on your phone. She looks at it for a long time. Then she says: I want to look into this further.

DGL's Core Mechanism Was Documented in 1971 — And in Egyptian Medical Records From 1550 BC

Clinical trials documenting DGL's mucosal repair mechanism were published in the journal Gut in 1971. The Ebers Papyrus — one of the oldest surviving medical texts dated to 1550 BC — records licorice root as a treatment for gastric and digestive complaints. Ancient Egyptian physicians were stimulating the prostaglandin E2 repair pathway 3,500 years before it had a name — and before the pharmaceutical industry existed to suppress it in favour of patentable alternatives.

Source: Gut journal (1971, 1973); Ebers Papyrus c. 1550 BCEgypt Has Drunk Licorice Root as a Daily Therapeutic Beverage for Millennia — At the Doses the Clinical Research Validated

GERD and esophagitis affect 18 to 27 percent of Western populations. In East Asia the rate is 2.5 to 7.8 percent. Traditional Chinese Medicine incorporates licorice root in approximately 70 percent of all classical formulas. The populations with the lowest rates of esophageal disease in the world have been consuming clinical-dose gut barrier support as a cultural habit for two thousand years. The clinical research confirms why this works. It simply has never been prescribed.

Source: PMC6358326, GERD prevalence meta-analysis; NCCIH on Traditional Chinese MedicineGerman Commission E Approved Chamomile for GI Inflammatory Disease in 1984 — The Same Pathway Expensive Biologics Target in Other Conditions

The German regulatory body for botanical medicines formally approved chamomile for inflammatory diseases of the gastrointestinal tract based on clinical evidence of NF-κB inhibition and cytokine reduction. This approval has existed since 1984. It has never made it into a GI prescribing guideline because chamomile cannot be patented. Not because the evidence is weaker. Because the revenue model does not exist for it.

Source: German Commission E (1984); apigenin NF-κB inhibition, Journal of Ethnopharmacology (2020)

Two months in, my father ran out for nine days waiting on a delayed order.

He kept taking the pantoprazole the whole time. Only the DGL and chamomile stopped.

By day three, the morning burn was back before his feet hit the floor.

By day six, the food that had started going down easily was catching again.

He called me, worried he had imagined the improvement.

The new bottle arrived. He restarted that evening.

Within a week the morning burn was gone again. The food went down again.

The PPI never changed the whole time. The only thing that changed was whether the two missing mechanisms were covered. That is when I stopped thinking of this as optional.